Reasons and Factors Contributing to Chinese Patients’ Preference for Ustekinumab in Crohn’s Disease: A Multicenter Cross-Sectional Study

Background and Aims: Ustekinumab (UST) was approved in China for treating moderate-to-severe Crohn’s disease (CD) in 2020. We aimed to identify the reasons and possible contributing factors for UST preference in Chinese patients with CD.Methods: We conducted a multicenter cross-sectional survey amon...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lingya Yao, Xiao Zhu, Bule Shao, Rongbei Liu, Zhilun Li, Lexi Wu, Jin Chen, Qian Cao
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	Crohn’s disease ustekinumab (UST) preference Chinese patients multicenter cross-sectional study Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/e2a228815b4e48f8bbc0dae0ec89d22a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e2a228815b4e48f8bbc0dae0ec89d22a
record_format	dspace
spelling	oai:doaj.org-article:e2a228815b4e48f8bbc0dae0ec89d22a2021-11-30T14:53:27ZReasons and Factors Contributing to Chinese Patients’ Preference for Ustekinumab in Crohn’s Disease: A Multicenter Cross-Sectional Study1663-981210.3389/fphar.2021.736149https://doaj.org/article/e2a228815b4e48f8bbc0dae0ec89d22a2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fphar.2021.736149/fullhttps://doaj.org/toc/1663-9812Background and Aims: Ustekinumab (UST) was approved in China for treating moderate-to-severe Crohn’s disease (CD) in 2020. We aimed to identify the reasons and possible contributing factors for UST preference in Chinese patients with CD.Methods: We conducted a multicenter cross-sectional survey among patients with moderate to severe CD who underwent UST treatment in 27 hospitals. Patients completed a 46-item questionnaire that included information on demographics, clinical characteristics, reasons in favor of UST and shared decision-making perception. Logistic regression analysis was performed to examine the predictive factors of different UST preferences.Results: Overall, 127 patients (73 males; mean age, 25.9 ± 9.9 years) completed the questionnaire. Most patients (74.8%) had biologic failure. The most common reason for the latest treatment disconnection was unresponsiveness to the previous medications. The major UST information sources were physicians (96.1%). Nearly half of the patients (44.9%) reported shared decision making regarding UST treatment. No difference was found in the decision-making patterns in terms of sex and age. The most influential reason for UST preference was “effectiveness” (77%, 98/127), followed by “safety” (65%, 83/127), “frequency of administration” (39%, 49/127), and “mode of administration” (37%, 47/127). Multivariate logistic regression analysis revealed that a positive self-rated health status was a contributing factor for UST preference with a low frequency of administration.Conclusion: This is the first multicenter survey of Chinese patients with CD to identify the possible contributing factors for UST preference. Treatment choice should be discussed with patients because individual preferences are determined by diverse factors.Lingya YaoXiao ZhuBule ShaoRongbei LiuZhilun LiLexi WuJin ChenQian CaoFrontiers Media S.A.articleCrohn’s diseaseustekinumab (UST)preferenceChinese patientsmulticenter cross-sectional studyTherapeutics. PharmacologyRM1-950ENFrontiers in Pharmacology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Crohn’s disease ustekinumab (UST) preference Chinese patients multicenter cross-sectional study Therapeutics. Pharmacology RM1-950
spellingShingle	Crohn’s disease ustekinumab (UST) preference Chinese patients multicenter cross-sectional study Therapeutics. Pharmacology RM1-950 Lingya Yao Xiao Zhu Bule Shao Rongbei Liu Zhilun Li Lexi Wu Jin Chen Qian Cao Reasons and Factors Contributing to Chinese Patients’ Preference for Ustekinumab in Crohn’s Disease: A Multicenter Cross-Sectional Study
description	Background and Aims: Ustekinumab (UST) was approved in China for treating moderate-to-severe Crohn’s disease (CD) in 2020. We aimed to identify the reasons and possible contributing factors for UST preference in Chinese patients with CD.Methods: We conducted a multicenter cross-sectional survey among patients with moderate to severe CD who underwent UST treatment in 27 hospitals. Patients completed a 46-item questionnaire that included information on demographics, clinical characteristics, reasons in favor of UST and shared decision-making perception. Logistic regression analysis was performed to examine the predictive factors of different UST preferences.Results: Overall, 127 patients (73 males; mean age, 25.9 ± 9.9 years) completed the questionnaire. Most patients (74.8%) had biologic failure. The most common reason for the latest treatment disconnection was unresponsiveness to the previous medications. The major UST information sources were physicians (96.1%). Nearly half of the patients (44.9%) reported shared decision making regarding UST treatment. No difference was found in the decision-making patterns in terms of sex and age. The most influential reason for UST preference was “effectiveness” (77%, 98/127), followed by “safety” (65%, 83/127), “frequency of administration” (39%, 49/127), and “mode of administration” (37%, 47/127). Multivariate logistic regression analysis revealed that a positive self-rated health status was a contributing factor for UST preference with a low frequency of administration.Conclusion: This is the first multicenter survey of Chinese patients with CD to identify the possible contributing factors for UST preference. Treatment choice should be discussed with patients because individual preferences are determined by diverse factors.
format	article
author	Lingya Yao Xiao Zhu Bule Shao Rongbei Liu Zhilun Li Lexi Wu Jin Chen Qian Cao
author_facet	Lingya Yao Xiao Zhu Bule Shao Rongbei Liu Zhilun Li Lexi Wu Jin Chen Qian Cao
author_sort	Lingya Yao
title	Reasons and Factors Contributing to Chinese Patients’ Preference for Ustekinumab in Crohn’s Disease: A Multicenter Cross-Sectional Study
title_short	Reasons and Factors Contributing to Chinese Patients’ Preference for Ustekinumab in Crohn’s Disease: A Multicenter Cross-Sectional Study
title_full	Reasons and Factors Contributing to Chinese Patients’ Preference for Ustekinumab in Crohn’s Disease: A Multicenter Cross-Sectional Study
title_fullStr	Reasons and Factors Contributing to Chinese Patients’ Preference for Ustekinumab in Crohn’s Disease: A Multicenter Cross-Sectional Study
title_full_unstemmed	Reasons and Factors Contributing to Chinese Patients’ Preference for Ustekinumab in Crohn’s Disease: A Multicenter Cross-Sectional Study
title_sort	reasons and factors contributing to chinese patients’ preference for ustekinumab in crohn’s disease: a multicenter cross-sectional study
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/e2a228815b4e48f8bbc0dae0ec89d22a
work_keys_str_mv	AT lingyayao reasonsandfactorscontributingtochinesepatientspreferenceforustekinumabincrohnsdiseaseamulticentercrosssectionalstudy AT xiaozhu reasonsandfactorscontributingtochinesepatientspreferenceforustekinumabincrohnsdiseaseamulticentercrosssectionalstudy AT buleshao reasonsandfactorscontributingtochinesepatientspreferenceforustekinumabincrohnsdiseaseamulticentercrosssectionalstudy AT rongbeiliu reasonsandfactorscontributingtochinesepatientspreferenceforustekinumabincrohnsdiseaseamulticentercrosssectionalstudy AT zhilunli reasonsandfactorscontributingtochinesepatientspreferenceforustekinumabincrohnsdiseaseamulticentercrosssectionalstudy AT lexiwu reasonsandfactorscontributingtochinesepatientspreferenceforustekinumabincrohnsdiseaseamulticentercrosssectionalstudy AT jinchen reasonsandfactorscontributingtochinesepatientspreferenceforustekinumabincrohnsdiseaseamulticentercrosssectionalstudy AT qiancao reasonsandfactorscontributingtochinesepatientspreferenceforustekinumabincrohnsdiseaseamulticentercrosssectionalstudy
_version_	1718406535869104128

Reasons and Factors Contributing to Chinese Patients’ Preference for Ustekinumab in Crohn’s Disease: A Multicenter Cross-Sectional Study

Ejemplares similares